Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Sep 27, 2023
Emerging Company Profile
Biotheus: fully-integrated mAb platform for optimized fast-follower products
China-based Biotheus goes from discovery to IND submission in about two years
BioCentury | Jun 30, 2023
Emerging Company Profile
Ratio: tuning the pharmacokinetics of radiotherapies
The company’s Trillium platform combines the tumor penetration of small molecules with the staying power of mAbs for its actinium-225 therapies
BioCentury | Mar 6, 2023
Finance
As clinical evidence mounts for bispecific, VCs back Bicara with $108M series B
Red Tree branches beyond West Coast sweet spot to co-lead with RA Capital in backing Biocon spinout
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
Items per page:
1 - 10 of 58